Healthcare provider profile · identity verified

Mark L Holbrook, M.D.

Internal Medicine · BOISE, ID · NPI 1205884616

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	664	193
Levothyroxine Sodium	Levothyroxine Sodium	486	127
Losartan Potassium	Losartan Potassium	331	99
Amlodipine Besylate	Amlodipine Besylate	304	84
Simvastatin	Simvastatin	240	74
Lisinopril	Lisinopril	224	68
Gabapentin	Gabapentin	181	65
Omeprazole	Omeprazole	180	58
Hydrochlorothiazide	Hydrochlorothiazide	170	49
Metoprolol Succinate	Metoprolol Succinate	167	49
Albuterol Sulfate Hfa	Albuterol Sulfate	144	68
Metformin Hcl	Metformin Hcl	135	40
Sertraline Hcl	Sertraline Hcl	130	39
Eliquis	Apixaban	126	36
Rosuvastatin Calcium	Rosuvastatin Calcium	117	40
Pravastatin Sodium	Pravastatin Sodium	112	29
Pantoprazole Sodium	Pantoprazole Sodium	99	26
Trazodone Hcl	Trazodone Hcl	97	26
Olmesartan Medoxomil	Olmesartan Medoxomil	95	24
Tramadol Hcl	Tramadol Hcl	95	41
Allopurinol	Allopurinol	94	24
Telmisartan	Telmisartan	89	24
Tamsulosin Hcl	Tamsulosin Hcl	80	26
Metformin Hcl Er	Metformin Hcl	77	24
Montelukast Sodium	Montelukast Sodium	75	23
Meloxicam	Meloxicam	73	21
Finasteride	Finasteride	69	20
Lansoprazole	Lansoprazole	68	19
Citalopram Hbr	Citalopram Hydrobromide	67	17
Famotidine	Famotidine	67	19
Chlorthalidone	Chlorthalidone	63	17
Glimepiride	Glimepiride	62	19
Metoprolol Tartrate	Metoprolol Tartrate	61	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	60	13
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	55	55
Furosemide	Furosemide	55	19
Celecoxib	Celecoxib	54	18
Clopidogrel	Clopidogrel Bisulfate	53	16
Potassium Chloride	Potassium Chloride	53	20
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	50	50
Carvedilol	Carvedilol	49	13
Ezetimibe	Ezetimibe	46	17
Spironolactone	Spironolactone	46	18
Januvia	Sitagliptin Phosphate	45	13
Fluoxetine Hcl	Fluoxetine Hcl	44	12
Jardiance	Empagliflozin	42	13
Estradiol	Estradiol	41	12
Donepezil Hcl	Donepezil Hcl	39	11
Venlafaxine Hcl Er	Venlafaxine Hcl	39	suppressed
Atenolol	Atenolol	38	suppressed
Fluticasone Propionate	Fluticasone Propionate	37	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	37	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	36	30
Alprazolam	Alprazolam	35	suppressed
Mounjaro	Tirzepatide	34	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	34	12
Zolpidem Tartrate	Zolpidem Tartrate	34	16
Candesartan Cilexetil	Candesartan Cilexetil	33	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	33	16
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	33	32
Alendronate Sodium	Alendronate Sodium	32	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	32	11
Methylprednisolone	Methylprednisolone	32	29
Diclofenac Sodium	Diclofenac Sodium	31	12
Duloxetine Hcl	Duloxetine Hcl	31	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	31	suppressed
Xarelto	Rivaroxaban	31	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	29	suppressed
Trulicity	Dulaglutide	28	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	27	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	26	suppressed
Warfarin Sodium	Warfarin Sodium	25	11
Bupropion Xl	Bupropion Hcl	24	suppressed
Humalog Kwikpen U-100	Insulin Lispro	24	suppressed
Ozempic	Semaglutide	24	suppressed
Ibandronate Sodium	Ibandronate Sodium	23	suppressed
Lorazepam	Lorazepam	21	suppressed
Lovastatin	Lovastatin	21	suppressed
Buspirone Hcl	Buspirone Hcl	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Tresiba Flextouch U-200	Insulin Degludec	20	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	19	15
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Diazepam	Diazepam	18	suppressed
Pregabalin	Pregabalin	18	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Hydrocortisone	Hydrocortisone	16	suppressed
Irbesartan	Irbesartan	16	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	16	suppressed
Verapamil Er	Verapamil Hcl	16	suppressed
Azithromycin	Azithromycin	15	14
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	15
Tresiba Flextouch U-100	Insulin Degludec	15	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	14	suppressed
Ramipril	Ramipril	14	suppressed
Armour Thyroid	Thyroid,pork	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	12
Fluticasone-Vilanterol	Fluticasone/Vilanterol	13	suppressed
Glipizide	Glipizide	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Ajovy Syringe	Fremanezumab-Vfrm	12	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	12	suppressed
Humalog	Insulin Lispro	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error